Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

The Cohort Construction Project of Peking University Third Hospital

9. august 2026 opdateret af: Peking University Third Hospital
The specific construction goals for this period include enrolling 100,000 individuals for dynamic follow-up, perfecting the biobank by collecting biological samples from 20,000 individuals, and gathering health questionnaire information from 30,000 people. The near-term goals emphasize the use of health check-up data combined with advanced artificial intelligence technologies to build disease prediction models and explore the association between retinal photographs and overall health status, which will assist in early screening and personalized interventions for high-risk populations. The medium- to long-term goals focus on biological age-related research, utilizing telomere length and multi-omics technologies to assess the differences between biological age and chronological age and analyze their key influencing factors. Data collection will be implemented through the health check-up centers of multiple campuses of PUTH.

Studieoversigt

Status

Status

Angiver den aktuelle rekrutteringsstatus eller den udvidede adgangsstatus.
Rekruttering

Betingelser

Betingelser

Den sygdom, lidelse, syndrom, sygdom eller skade, der undersøges. På ClinicalTrials.gov kan tilstande også omfatte andre sundhedsrelaterede problemer, såsom levetid, livskvalitet og sundhedsrisici.

Intervention / Behandling

Intervention / Behandling

En proces eller handling, der er i fokus for en klinisk undersøgelse. Interventioner omfatter lægemidler, medicinsk udstyr, procedurer, vacciner og andre produkter, der enten er til undersøgelse eller allerede er tilgængelige. Interventioner kan også omfatte ikke-invasive tilgange, såsom uddannelse eller ændring af kost og motion.

Detaljeret beskrivelse

The construction of a health check-up follow-up cohort holds significant importance for public health research. Since its establishment in 2022, the Health Check-up Cohort of Peking University Third Hospital (PUTH) has been operational for three years. The cohort features comprehensive health check-up indicators, including physical examination, biochemical tests, cancer screening, and 13 other major categories of indicators. It is equipped with a robust data management system and collaborates with the Clinical Epidemiology Research Center and the biobank. A multidimensional database has been established, covering health check-up information, health questionnaires, and biological samples of the study subjects. The cohort adopts a bidirectional study design, with the retrospective part covering individuals who underwent health check-ups since 2011 and the prospective part continuously enrolling subjects since 2022. As of 2023, the PUTH Health Check-up Cohort has collected health check-up data from over 80,000 study subjects, with the longest follow-up duration reaching 12 years, forming a longitudinal health database with continuous follow-up.

The cohort construction project has achieved favorable research outcomes, with a total of 14 academic papers published, including 8 SCI papers, and two invention patents granted. In addition, the cohort has collaborated with clinical departments within the hospital and has previously received funding from both internal and external horizontal and vertical projects. The primary focus has been on conducting research on medical reference value ranges and disease prevention and control among the health check-up cohort population. Building on the solid foundation of previous work, the cohort study will continue to optimize and expand, aiming to align with international large-scale cohorts by constructing a health check-up cohort with a large sample size, long follow-up duration, and high follow-up density.

The specific construction goals for this period include enrolling 100,000 individuals for dynamic follow-up, perfecting the biobank by collecting biological samples from 20,000 individuals, and gathering health questionnaire information from 30,000 people. The near-term goals emphasize the use of health check-up data combined with advanced artificial intelligence technologies to build disease prediction models and explore the association between retinal photographs and overall health status, which will assist in early screening and personalized interventions for high-risk populations. The medium- to long-term goals focus on biological age-related research, utilizing telomere length and multi-omics technologies to assess the differences between biological age and chronological age and analyze their key influencing factors. Data collection will be implemented through the health check-up centers of multiple campuses of PUTH.

The construction of this health check-up cohort provides a solid data foundation for the prevention of chronic diseases, individualized health management, and research on healthy aging. Through long-term follow-up and large-scale data collection, it can reveal disease risk factors, develop early prediction models, and in combination with biomarkers and multi-omics technologies, it helps explore the relationship between biological age and health status, promoting the development of precision medicine and the optimization of public health policies.

Undersøgelsestype

Undersøgelsestype

Beskriver karakteren af ​​en klinisk undersøgelse. Undersøgelsestyper omfatter interventionelle undersøgelser (også kaldet kliniske forsøg), observationsundersøgelser (herunder patientregistre) og udvidet adgang.
Observationel

Tilmelding (Anslået)

Tilmelding

Antallet af deltagere i en klinisk undersøgelse. Den "forventede" tilmelding er det mål for antallet af deltagere, som forskerne skal bruge til undersøgelsen.
100000

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiekontakt

Navn og kontaktoplysninger for den person, der kan besvare spørgsmål om tilmelding til en klinisk undersøgelse. Hvert sted, hvor undersøgelsen udføres, kan også have en specifik kontaktperson, som kan være bedre i stand til at besvare disse spørgsmål.

Undersøgelse Kontakt Backup

Studiesteder

  • Kina
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100191
        • Rekruttering
        • Physical Examination Center, Peking University Third Hospital
        • Kontakt:
        • Kontakt:
          • Peng Wang, MMed
          • Telefonnummer: +86 13601015655
          • E-mail: bysywp@126.com
        • Ledende efterforsker:
          • Peng Wang, MMed
        • Underforsker:
          • Liyuan Tao, PhD
        • Underforsker:
          • Ying Che, MS

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Berettigelseskriterier

De nøglekrav, som personer, der ønsker at deltage i et klinisk studie, skal opfylde eller de egenskaber, de skal have. Kvalifikationskriterier består af både inklusionskriterier (som er nødvendige for at en person kan deltage i undersøgelsen) og eksklusionskriterier (som forhindrer en person i at deltage). Typer af berettigelseskriterier omfatter, om en undersøgelse accepterer raske frivillige, har alders- eller aldersgruppekrav eller er begrænset af køn.

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

The study population consists of individuals who voluntarily undergo health examinations at the Physical Examination Center of Peking University Third Hospital. Participants are recruited from group health examination populations (including employees from functional community units such as government agencies, schools, and enterprises) who have undergone at least two consecutive health examinations at the center. The study includes both retrospective and prospective participants, with long-term follow-up and biospecimen collection (serum) stored in the hospital's biobank.

Beskrivelse

Inclusion Criteria:

  • Age ≥ 18 years. Participants must be from group health examination populations who have undergone at least two consecutive health examinations at our Physical Examination Center.

Exclusion Criteria:

  • Failure to provide informed consent. Incomplete data, including incomplete health examination self-administered questionnaires.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Kohorter og interventioner

Gruppe / kohorte

Gruppe / kohorte

En gruppe eller undergruppe af deltagere i et observationsstudie, der vurderes for biomedicinske eller sundhedsmæssige resultater.
Intervention / Behandling

Intervention / Behandling

En proces eller handling, der er i fokus for en klinisk undersøgelse. Interventioner omfatter lægemidler, medicinsk udstyr, procedurer, vacciner og andre produkter, der enten er til undersøgelse eller allerede er tilgængelige. Interventioner kan også omfatte ikke-invasive tilgange, såsom uddannelse eller ændring af kost og motion.
Functional Community Health Examination Cohort
This cohort consists of employees from functional community units (such as government agencies, schools, and enterprises) who undergo regular health examinations at the Physical Examination Center of Peking University Third Hospital. The cohort integrates both retrospective and prospective data, with long-term follow-up and biospecimen collection (serum) stored in the hospital's biobank.
Andet: observational study
This is an observational study designed to investigate the mental health status and its influencing factors in the general physical examination population. No interventions are assigned to participants based on a protocol.

Hvad måler undersøgelsen?

Primære resultatmål

Primære resultatmål

I et klinisk studies protokol er det planlagte resultatmål, der er det vigtigste for at evaluere effekten af ​​en intervention/behandling. De fleste kliniske undersøgelser har ét primært resultatmål, men nogle har mere end ét.
Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Systolic and Diastolic Blood Pressure
Tidsramme: through study completion, an average of 3 year
Blood pressure will be measured using a standardized mercury sphygmomanometer after at least 5 minutes of rest in a seated position. Both systolic blood pressure (SBP) and diastolic blood pressure (DBP) will be recorded.
through study completion, an average of 3 year
Fasting Lipid Profile (Total Cholesterol, Triglycerides, LDL-C, and HDL-C)
Tidsramme: through study completion, an average of 3 year
Venous blood samples will be collected after at least 8 hours of overnight fasting. Serum levels of total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) will be measured using an automated biochemical analyzer at the central laboratory of Peking University Third Hospital.
through study completion, an average of 3 year
Fasting Blood Glucose (FBG)
Tidsramme: through study completion, an average of 3 year
Fasting venous blood samples will be collected after at least 8 hours of overnight fasting. Serum glucose levels will be measured using an automated biochemical analyzer at the central laboratory of Peking University Third Hospital.
through study completion, an average of 3 year
Glycated Hemoglobin (HbA1c)
Tidsramme: through study completion, an average of 3 year
Fasting venous blood samples will be collected and analyzed using high-performance liquid chromatography (HPLC) at the central laboratory of Peking University Third Hospital. HbA1c reflects average blood glucose levels over the previous 2 to 3 months.
through study completion, an average of 3 year
Complete Blood Count (CBC)
Tidsramme: through study completion, an average of 3 year
Fasting venous blood samples will be collected and analyzed using an automated hematology analyzer at the central laboratory of Peking University Third Hospital. Key parameters include white blood cell count (WBC), red blood cell count (RBC), hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and platelet count (PLT).
through study completion, an average of 3 year
Routine Urinalysis
Tidsramme: through study completion, an average of 3 year
Midstream clean-catch urine specimens will be collected and analyzed using an automated urine analyzer and microscopy at the central laboratory of Peking University Third Hospital. Key parameters include urine specific gravity, pH, protein, glucose, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase, and microscopic examination of red blood cells, white blood cells, and casts.
through study completion, an average of 3 year
Liver Function Panel
Tidsramme: through study completion, an average of 3 year
Fasting venous blood samples will be collected and analyzed using an automated biochemical analyzer at the central laboratory of Peking University Third Hospital. Key parameters include alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin (TBIL), direct bilirubin (DBIL), total protein (TP), and albumin (ALB).
through study completion, an average of 3 year
Renal Function Panel
Tidsramme: through study completion, an average of 3 year
Fasting venous blood samples will be collected and analyzed using an automated biochemical analyzer at the central laboratory of Peking University Third Hospital. Key parameters include serum creatinine (Cr), blood urea nitrogen (BUN), uric acid (UA), and estimated glomerular filtration rate (eGFR) calculated using the CKD-EPI or MDRD equation.
through study completion, an average of 3 year
Pulmonary Assessment
Tidsramme: through study completion, an average of 3 year
Chest X-ray or low-dose chest CT will be performed according to standardized protocols at the Radiology Department of Peking University Third Hospital. Findings will be interpreted by certified radiologists. Results will be reported as presence or absence of pulmonary abnormalities (e.g., nodules, infiltrates, or other clinically significant findings).
through study completion, an average of 3 year
Abdominal Ultrasound Assessment
Tidsramme: through study completion, an average of 3 year
Abdominal ultrasound will be performed according to standardized protocols at the Radiology Department of Peking University Third Hospital for evaluation of the liver, gallbladder, pancreas, spleen, and kidneys. Findings will be interpreted by certified radiologists. Results will be reported as presence or absence of abnormalities in each organ.
through study completion, an average of 3 year
Carotid Artery Ultrasound Assessment
Tidsramme: through study completion, an average of 3 year
Carotid artery ultrasound will be performed according to standardized protocols at the Radiology Department of Peking University Third Hospital for assessment of carotid intima-media thickness (CIMT) and plaque detection. CIMT will be measured in millimeters (mm). Plaque will be reported as present or absent. All findings will be interpreted by certified radiologists.
through study completion, an average of 3 year

Sekundære resultatmål

Sekundære resultatmål

I en klinisk undersøgelses protokol er et planlagt resultatmål, der ikke er lige så vigtigt som det primære resultatmål for at evaluere effekten af ​​en intervention, men som stadig er af interesse. De fleste kliniske undersøgelser har mere end ét sekundært resultatmål.
Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
BMI
Tidsramme: through study completion, an average of 3 year
Body composition will be measured using bioelectrical impedance analysis (BIA) or dual-energy X-ray absorptiometry (DXA) at the Physical Examination Center of Peking University Third Hospital. Body mass index (BMI) will be calculated as weight in kilograms divided by height in meters squared (kg/m²).
through study completion, an average of 3 year
Body Fat Percentage
Tidsramme: through study completion, an average of 3 year
Body composition will be measured using bioelectrical impedance analysis (BIA) or dual-energy X-ray absorptiometry (DXA) at the Physical Examination Center of Peking University Third Hospital. Body fat percentage (BFP) will be reported as a percentage (%).
through study completion, an average of 3 year
Visceral Fat Area
Tidsramme: through study completion, an average of 3 year
Body composition will be measured using bioelectrical impedance analysis (BIA) or dual-energy X-ray absorptiometry (DXA) at the Physical Examination Center of Peking University Third Hospital. Visceral fat area (VFA) will be reported in square centimeters (cm²).
through study completion, an average of 3 year
Skeletal Muscle Mass
Tidsramme: through study completion, an average of 3 year
Body composition will be measured using bioelectrical impedance analysis (BIA) or dual-energy X-ray absorptiometry (DXA) at the Physical Examination Center of Peking University Third Hospital. Skeletal muscle mass (SMM) will be reported in kilograms (kg).
through study completion, an average of 3 year
Handgrip Strength
Tidsramme: through study completion, an average of 3 year
Physical fitness will be assessed by trained exercise physiologists at the Physical Examination Center of Peking University Third Hospital using standardized protocols. Handgrip strength will be measured using a handheld dynamometer and reported in kilograms (kg).
through study completion, an average of 3 year
Back Strength
Tidsramme: through study completion, an average of 3 year
Back strength will be assessed by trained exercise physiologists at the Physical Examination Center of Peking University Third Hospital using a back dynamometer following standardized protocols. Results will be measured and reported in kilograms (kg).
through study completion, an average of 3 year
Vertical Jump Height
Tidsramme: through study completion, an average of 3 year
Vertical jump height will be assessed by trained exercise physiologists at the Physical Examination Center of Peking University Third Hospital using a force platform or jump mat following standardized protocols. Results will be measured and reported in centimeters (cm).
through study completion, an average of 3 year
Estimated VO₂max
Tidsramme: through study completion, an average of 3 year
Cardiorespiratory function will be assessed by trained exercise physiologists at the Physical Examination Center of Peking University Third Hospital using standardized protocols. Estimated maximal oxygen uptake (VO₂max) will be calculated and reported in milliliters per kilogram per minute (ml/kg/min).
through study completion, an average of 3 year

Andre resultatmål

Andre resultatmål

For kliniske forsøg en planlagt måling beskrevet i protokollen, der bruges til at bestemme effekten af ​​en intervention/behandling på deltagerne. Til observationsstudier, en måling eller observation, der bruges til at beskrive mønstre af sygdomme eller egenskaber eller sammenhænge med eksponeringer, risikofaktorer eller behandling. Typer af resultatmål omfatter primært resultatmål og sekundært resultatmål.
Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Thyroid Function Panel
Tidsramme: Measured at baseline and at each annual health examination visit
Fasting venous blood samples will be collected and analyzed using an automated chemiluminescence immunoassay analyzer at the central laboratory of Peking University Third Hospital. Key parameters include thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), and free thyroxine (FT4). Additional parameters (e.g., total T3, total T4, anti-thyroglobulin antibody [TG-Ab], and anti-thyroid peroxidase antibody [TPO-Ab]) may be measured as clinically indicated.
Measured at baseline and at each annual health examination visit
Inflammatory Biomarker Panel
Tidsramme: Measured at baseline and at each annual health examination visit
Fasting venous blood samples will be collected and analyzed at the central laboratory of Peking University Third Hospital. The inflammatory biomarker panel includes high-sensitivity C-reactive protein (hsCRP) measured by immunoturbidimetry, and a panel of serum cytokines (including but not limited to IL-6, TNF-α, IL-10, and IL-17A) measured using a multiplex immunoassay system. Additional inflammatory markers such as white blood cell count (WBC) and ferritin will also be assessed. All measurements will be performed following standardized protocols.
Measured at baseline and at each annual health examination visit

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Sponsor

Den organisation eller person, der igangsætter undersøgelsen, og som har myndighed og kontrol over undersøgelsen.
Peking University Third Hospital

Efterforskere

Efterforskere

En forsker involveret i et klinisk studie. Beslægtede termer omfatter stedets principal investigator, site sub-investigator, studieformand, undersøgelsesleder og undersøgelseshovedinvestigator.
  • Studieleder: Peng Wang, MMed, Peking University Third Hospital

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

Studiestart

Den faktiske dato, hvor den første deltager blev tilmeldt en klinisk undersøgelse. Den "forventede" undersøgelses startdato er den dato, som forskerne tror vil være undersøgelsens startdato.
21. februar 2025

Primær færdiggørelse (Anslået)

Primær færdiggørelse

Den dato, hvor den sidste deltager i et klinisk studie blev undersøgt eller modtog en intervention for at indsamle endelige data for det primære resultatmål. Hvorvidt det kliniske studie sluttede i henhold til protokollen eller blev afsluttet, påvirker ikke denne dato. For kliniske undersøgelser med mere end ét primært resultatmål med forskellige afslutningsdatoer refererer dette udtryk til den dato, hvor dataindsamlingen er afsluttet for alle de primære resultatmål. Den "forventede" primære afslutningsdato er den dato, som forskerne tror vil være den primære afslutningsdato for undersøgelsen.
31. december 2027

Studieafslutning (Anslået)

Studieafslutning

Den dato, hvor den sidste deltager i et klinisk studie blev undersøgt eller modtog en intervention/behandling for at indsamle endelige data for de primære resultatmål, sekundære udfaldsmål og uønskede hændelser (det vil sige den sidste deltagers sidste besøg). Den "forventede" undersøgelses afslutningsdato er den dato, som forskerne tror vil være undersøgelsens afslutningsdato.
31. december 2027

Datoer for studieregistrering

Først indsendt

Først indsendt

Den dato, hvor undersøgelsens sponsor eller investigator første gang indsendte en undersøgelsespost til ClinicalTrials.gov. Der er typisk en forsinkelse på et par dage mellem den første indsendte dato og postens tilgængelighed på ClinicalTrials.gov (den første offentliggjorte dato).
16. juli 2026

Først indsendt, der opfyldte QC-kriterier

Først indsendt, der opfyldte QC-kriterier

Den dato, hvor undersøgelsens sponsor eller investigator første gang indsender en undersøgelsespost, der er i overensstemmelse med National Library of Medicine (NLM) kvalitetskontrol (QC) gennemgangskriterier. Sponsoren eller investigatoren skal muligvis revidere og indsende en undersøgelsespost en eller flere gange, før NLM's kvalitetskontrolkriterier er opfyldt. Det er sponsorens eller investigatorens ansvar at sikre, at undersøgelsesposten er i overensstemmelse med NLM QC-gennemgangskriterierne.
9. august 2026

Først opslået (Faktiske)

Først opslået

Datoen, hvor undersøgelsesposten først var tilgængelig på ClinicalTrials.gov efter National Library of Medicine (NLM) kvalitetskontrol (QC) gennemgang er afsluttet. Der er typisk en forsinkelse på et par dage mellem den dato, hvor undersøgelsens sponsor eller investigator indsendte undersøgelsesposten, og den første offentliggjorte dato.
12. august 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

Sidste opdatering sendt

Den seneste dato, hvor ændringer i en undersøgelsespost blev gjort tilgængelig på ClinicalTrials.gov. Der kan være en forsinkelse mellem det tidspunkt, hvornår ændringerne blev indsendt til ClinicalTrials.gov af undersøgelsens sponsor eller investigator (datoen for sidste opdatering afsendt) og den sidste opdatering, der blev sendt.
12. august 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

Den seneste dato, hvor undersøgelsens sponsor eller investigator indsendte ændringer til en undersøgelsespost, der er i overensstemmelse med National Library of Medicine (NLM) kvalitetskontrol (QC) gennemgangskriterier. Det er sponsorens eller investigatorens ansvar at sikre, at undersøgelsesposten er i overensstemmelse med NLM QC-gennemgangskriterierne.
9. august 2026

Sidst verificeret

Sidst verificeret

Den seneste dato, hvor undersøgelsens sponsor eller investigator bekræftede oplysningerne om en klinisk undersøgelse på ClinicalTrials.gov som nøjagtige og aktuelle. Hvis en undersøgelse med rekrutteringsstatus som rekruttering; rekrutterer endnu ikke; eller aktiv, ikke rekruttering er ikke blevet bekræftet inden for de seneste 2 år, er undersøgelsens rekrutteringsstatus vist som ukendt.
1. juli 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

Andre undersøgelses-id-numre

Andre identifikatorer eller ID-numre end NCT-nummeret, der er tildelt til en klinisk undersøgelse af undersøgelsens sponsor, finansieringsgivere eller andre. Disse numre kan omfatte unikke identifikatorer fra andre forsøgsregistre og National Institutes of Health-bevillingsnumre.
  • BYSYDL2024010
  • IRB00006761-M20250131 (Anden identifikator: Peking University Third Hospital Medical Science Research Ethics Committee)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Cookieindstillinger

Vi bruger cookies for at sikre, at vi giver dig den bedste oplevelse på vores hjemmeside. For flere detaljer skal du læse omhyggeligt vores Politik om beskyttelse af personlige oplysninger og cookies. ...>>>Du kan når som helst ændre dine præferencer eller trække dit samtykke tilbage ved at slette cookies fra din hjemmeside eller computer som beskrevet i politikken. Accepter det og vælg dine præferencer ved at markere de tilsvarende felter i afsnittet "Administrer indstillinger" nedenfor. Læs vores servicevilkår omhyggeligt, inden du fortsætter med at bruge nogen del af dette websted.
«Administrer indstillinger